Abstract
The accurate diagnosis and follow-up of neuroendocrine and neuroectodermal tumors at the time of diagnosis are crucial in managing the treatment process for patients. Neuroendocrine tumors (NETs) are rare and heterogeneous tumors that arise from neuroendocrine cells. They are most commonly found in the digestive system and lungs and can present diverse clinical symptoms due to their hormone-secreting potential. On the other hand, neuroectodermal tumors originate from neural crest-derived cells and can manifest in various clinical conditions. Primitive neuroectodermal tumors, such as neuroblastoma and medulloblastoma, are part of this group. Hybrid imaging techniques, such as positron emission tomography/magnetic resonance, offer significant advantages in staging, restaging, assessing treatment response, and determining metabolic activity and receptor expression of these tumors. These techniques combine both functional and anatomical data, enabling more accurate evaluations and treatment planning.
Keywords: Positron emission tomography/magnetic resonance, oncological imaging, neuroendocrine tumors, neuroectodermal tumors, FDG PET, Ga-68 DOTATATE
References
Mirpour S, Ghadimi M, Pawlik TM, Kamel IR. Imaging of neuroendocrine tumors. Neuroendocrine tumors: surgical evaluation and management. Springer International Publishing. 2021:17-34.
Yordanova A, Biersack HJ, Ahmadzadehfar H. Advances in molecular ımaging and radionuclide therapy of neuroendocrine tumors. J Clin Med. 2020;9:3679.
Pirasteh A, Riedl C, Mayerhoefer ME, Giancipoli RG, Larson SM, Bodei L. PET/MRI for neuroendocrine tumors: a match made in heaven or just another hype? Clin Transl Imaging. 2019;7:405-413.
Virarkar MK, Montanarella M, Itani M, Calimano-Ramirez L, Gopireddy D, Bhosale P. PET/MRI imaging in neuroendocrine neoplasm. Abdom Radiol (NY). 2023;48:3585-3600.
Rajamohan N, Khasawneh H, Singh A, et al. PET/CT and PET/MRI in neuroendocrine neoplasms. Abdom Radiol (NY). 2022;47:4058-4072.
Abid C, Tannoury J, Uzzan M, et al. Interest of ıntegrated whole-body PET/MR imaging in gastroenteropancreatic neuroendocrine neoplasms: a retro-prospective study. Cancers (Basel). 2024;16:2372.
Ryder SJ, Love AJ, Duncan EL, Pattison DA. PET detectives: Molecular imaging for phaeochromocytomas and paragangliomas in the genomics era. Clin Endocrinol (Oxf). 2021;95:13-28.
Taïeb D, Hicks RJ, Hindié E, et al. European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging. 2019;46:2112-2137.
Carrasquillo JA, Chen CC, Jha A, et al. Imaging of pheochromocytoma and paraganglioma. J Nucl Med. 2021;62:1033-1042.
Bozkurt MF, Virgolini I, Balogova S, et al. Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F-DOPA. Eur J Nucl Med Mol Imaging. 2017;44:1588-1601.
Samim A, Tytgat GAM, Bleeker G, et al. Nuclear medicine imaging in neuroblastoma: current status and new developments. J Pers Med. 2021;11:270.
Bar-Sever Z, Biassoni L, Shulkin B, et al. Guidelines on nuclear medicine imaging in neuroblastoma. Eur J Nucl Med Mol Imaging. 2018;45:2009-2024.
Liang J, Xu Y, Wang F, Li Q, zhu yanfang. The value of 18F-FDG PET/MR whole body imaging in staging of pediatric neuroblastoma. Journal of Nuclear Medicine. 2020;61:122.
Gururangan S, Hwang E, Herndon JE 2nd, Fuchs H, George T, Coleman RE. [18F]fluorodeoxyglucose-positron emission tomography in patients with medulloblastoma. Neurosurgery. 2004;55:1280-1288.
Magnetic resonance imaging spectrum of medulloblastoma. Neuroradiology. 2011;53:387-396.
Esiashvili N, Goodman M, Marcus RB Jr. Changes in incidence and survival of Ewing sarcoma patients over the past 3 decades: Surveillance Epidemiology and End Results data. J Pediatr Hematol Oncol. 2008;30:425-430.
Strauss SJ, Frezza AM, Abecassis N, et al. Bone sarcomas: ESMO-EURACAN-GENTURIS-ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2021;32:1520-1536.
Seth N, Seth I, Bulloch G, et al. 18 F-FDG PET and PET/CT as a diagnostic method for Ewing sarcoma: a systematic review and meta-analysis. Pediatr Blood Cancer. 2022;69:e29415.
Franzius C, Sciuk J, Schmidt CB, Jürgens H, Schober O. Evaluation of chemotherapy response in primary bone tumors with F-18 FDG positron emission tomography compared with histologically assessed tumor necrosis. Clin Nucl Med. 2000;25:874-881.
Chodyla M, Barbato F, Dirksen U, et al. Utility of Integrated PET/MRI for the primary diagnostic work-up of patients with ewing sarcoma: preliminary results. Diagnostics (Basel). 2022;12:2278.
